Is A Short Squeeze Ahead for Spectrum Pharmaceuticals (SPPI)?
moreView todays social media effects on SPPIView the latest stocks trending across Twitter. Click to view dashboardSee who Spectrum is hiring next, click here to view […]
SPPI
Spectrum Pharmaceuticals Management Discusses Q4 2013 Results – Earnings Call Transcript
[at Seeking Alpha] – Rajesh C. Shrotriya Thank you, Shiv, and thank you, everyone for joining us this afternoon. I’m very pleased to share with you the progress we have made during the fourth quarter and the critical corporate … moreView todays social media effects on SPPIView the latest stocks trending across Twitter. Click to view dashboardSee who Spectrum is […]
Spectrum Pharmaceuticals Announces Fourth Quarter 2013 Financial Results Teleconference and Webcast
[Business Wire] – Spectrum Pharmaceuticals , a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, moreView todays social media effects on SPPIView the latest stocks trending across Twitter. Click to view dashboardSee who Spectrum is hiring next, click here to view […]
Investors are betting against Spectrum Pharmaceuticals (SPPI), Should You?
moreView todays social media effects on SPPIView the latest stocks trending across Twitter. Click to view dashboardSee who Spectrum is hiring next, click here to view […]
3 Under-the-Radar Biotech Stocks You Need to Watch in 2014
moreView todays social media effects on SPPIView the latest stocks trending across Twitter. Click to view dashboardSee who Spectrum is hiring next, click here to view […]
Spectrum Pharm. Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate
[at noodls] – Spectrum Pharmaceuticals Initiates Phase 2 Study of Long-Acting GCSF Drug Candidate, SPI-2012, for the Treatment of Chemotherapy-Induced Neutropenia In U.S.-based Phase 1 trial, SPI-2012 demonstrated increase … moreView todays social media effects on SPPIView the latest stocks trending across Twitter. Click to view dashboardSee who Spectrum is hiring next, click here to view […]
PropThink: SPPI Strong 3Q; Guidance Raised, Fusilev Growing, Estimates To Rise
[ACN Newswire] – By David MoskowitzSpectrum Pharmaceuticals (NASDAQ:SPPI) reported adjusted 3Q 2012 earnings per share (EPS) of $0.42, beating the Consensus estimate of $0.27. Revenues for the period came in at $69.0 million … moreView todays social media effects on SPPIView the latest stocks trending across Twitter. Click to view dashboard […]
PropThink: SGNT Generic Leucovorin Launches; SPPI Should Absorb The News Well
[ACN Newswire] – By David MoskowitzShares of Spectrum Pharmaceuticals (NASDAQ:SPPI) have been under pressure as investors await the supply of generic leucovorin to increase and compete with SPPI’s branded cancer treatment, … moreView todays social media effects on SPPIView the latest stocks trending across Twitter. Click to view dashboard […]
PropThink: Five More Years of Patent Protection, and Revenue, for Spectrum Pharmaceuticals
[ACN Newswire] – By Jake KingSpectrum Pharmaceuticals (NASDAQ:SPPI) announced Monday morning that the company received a five-year extension on its patent for Folotyn, which lengthens the drug’s market exclusivity from … moreView todays social media effects on SPPIView the latest stocks trending across Twitter. Click to view dashboard […]
